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Abstract  
MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast can-
cer. Down-regulation of microRNA-148a (miR-148a) has been reported in certain cancer types. However, the 
biological role of miR-148a and its related targets in breast cancer are unknown yet. In this study, we showed that 
the level of miR-148a was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (ERBB3) is a direct target of miR-148a in human breast cancer cells through direct binding 
of miR-148a to ERBB3 3’-UTR region. Overexpression of miR-148a in MCF7 cells inhibited ERBB3 expression, 
blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased 
HIF-1α expression. Furthermore, forced expression of miR-148a attenuated tumor angiogenesis in vivo. Our re-
sults identify ERBB3 as a direct target of miR-148a, and provide direct evidence that miR-148a inhibits tumor an-
giogenesis through ERBB3 and its downstream signaling molecules. This information would be helpful for target-
ing the miR-148a/ERBB3 pathway for breast cancer prevention and treatment in the future.
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INTRODUCTION
Breast cancer is the most common cancer in women 
with more than 400,000 deaths each year worldwide. 
MicroRNAs (miRNAs) are a class of small noncod-
ing RNAs that have been identified as a new kind 
of gene expression regulators through targeting the 
3’-untranslated region (UTR) of mRNAs for trans-
lational repression or degradation[1,2]. MiRNAs are 
differentially expressed in various human cancers, 
functioning either as oncogenes or tumor suppressors 
by controlling the expression of their target genes[3,4]. 
Some miRNAs were related to cancer biopathological 
features like vascular invasion, lymph node metasta-
sis, tumor stage and cell proliferation[3-5]. Recent stud-
ies have shown that reduced expression of miR-148a 
occurs in chronic lymphocytic leukemia, gastrointes-
tinal cancer, and esophageal carcinoma[5-8] and is cor-
related with the outcome of certain malignancies[8,9]. 
The hypermethylation-associated miR-148a silencing 
has also been reported to be correlated with human 
cancer metastasis[10]. Overexpression of miR-148a at-
tenuated paclitaxel resistance of hormone-refractory, 
drug-resistant prostate cancer PC3 cells by regulat-
ing mitogen- and stress-activated kinase 1 (MSK1) 
expression[11]. Known direct targets of miR-148a in-
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clude transcription growth factor-β-induced factor 2 
(TGIF2), DNA (cytosine-5-)-methyltransferase 3β 
(DNMT3b), pregnane X receptor (PXR), neddylation-
dissociated 1, and DNA methyltransferase-1[10,12-15]. 
However, the biological roles of miR-148a and the tar-
get genes in breast cancer have not yet been defined.
V-erb-b2 erythroblastic leukemia viral oncogene 
homolog 3 (ERBB3) is a member of the epidermal 
growth factor receptor (EGFR) family, which consists 
of EGFR/ERBB1, ERBB2/Neu/HER2, ERBB3, and 
ERBB4. Since ERBB3 lacks intrinsic kinase activity, 
signal transduction occurs through formation of het-
erodimers with ERBB2 and other members. The bind-
ing of peptides of the EGF-related growth factor fam-
ily to the extracellular domain of the ERBB receptors 
causes the formation of homo- and heterodimers. Lig-
and binding induces intrinsic receptor kinase activity 
and then stimulates intracellular signaling cascades, 
including the phosphatidylinositol-3 kinase (PI3K)/
AKT and MAPKs cascade[16,17]. Elevated expression 
of ERBB3 is frequently observed in breast cancer, 
which may play an important role in breast cancer 
progression and chemotherapy resistance[18,19]. Recent 
studies have demonstrated that miR-125 and miR-205 
act as tumor suppressors through directly targeting 
ERBB3[20,21].
Tumor angiogenesis is required for tumor develop-
ment and growth in which hypoxia-inducible factor 
1α (HIF-1α) plays a pivotal role[22,23].  In the present 
study, we want to identify novel target(s) of miR-
148a, which may be related to tumor angiogenesis, 
identify signaling pathways that are regulated by miR-
148a, and determine the direct role of miR-148a in 
angiogenesis. This will provide direct evidence for the 
role and potential mechanism of miR-148a in regulat-
ing breast tumor angiogenesis.
MATERIALS AND METHODS
Cell culture and reagents
Human breast cancer cells MCF7 and embryonic 
kidney cells HEK293 were cultured in Dulbecco’s 
Modified Eagle Media (DMEM) supplemented with 
10% fetal bovine serum, 100 units/mL penicillin, 100 
mg/mL streptomycin, and 5% CO2 at 37°C. ERBB3 
antibodies were purchased from Bioworld Technol-
ogy (Louis Park, MN, USA). Antibodies against 
phospho-AKT, AKT, phospho-ERK1/2, ERK, phos-
pho-p70S6K1 and p70S6K1 were purchased from 
Cell Signaling Technology (MA, USA), Antibodies 
against HIF-1α was from BD Biosciences (NJ, USA). 
Antibodies against GAPDH were from Kang-Cheng 
(Shanghai, China). Puromycin and β-actin monoclonal 
antibody were from Sigma (St. Louis, MO, USA). 
Matrigel was from BD Biosciences (Franklin Lakes, 
NJ, USA). Trizol was purchased from Invitrogen 
(Carlsbad, CA, USA).
Lentivirus packaging and stable cell lines es-
tablishment
The lentiviral vectors with RFP tag carrying scram-
bled miRNA (pLe-miR-SCR), miR-148a (pLe-miR-
148a), and packaging kit were purchased from Thermo 
Scientific (Huntsville, AL, USA). Lentiviral packag-
ing was performed using HEK293T cells by following 
the manufacturer’s manual. MCF7 cells were infected 
with lentiviruses, and selected by puromycin to obtain 
stable cell lines expressing miR-SCR and miR-148a. 
RT-PCR and TaqMan real-time PCR analysis 
of miR-148a
Total RNAs of MCF7 cells were extracted using 
Trizol reagent according to the manufacturer’s in-
struction. The stem-loop RT-PCR assay was used 
to quantify the miRNA expression levels as was de-
scribed previously[35,36]. The PCR primers used were 
as follows: miR-148a RT primer: 5’-CTCAACT-
GGTGTCGTGGAGTCGGCAATTCAGTTGA-
GACAAAGTT-3’. miR-148a PCR primers: sense: 
5’-ACACTCCAGCTGGGTCAGTGCACTACA-
GAA-3’; anti-sense: 5’-TGGTGTCGTGGAGTCG-3’. 
U6 RT primer: 5’-TGGTGTCGTGGAGTCG-3’. 
U6 PCR primers: sense: 5’-CTCGCTTCGGCAG-
CACA-3’; anti-sense: 5’-AACGCTTCACGAATTT-
GCGT-3’. PCR products were separated on 1.5% 
agarose gels, stained with ethidium bromide, and 
visualized under UV light. The levels of miR-148a 
in MCF7, T47D and MCF10A cells were tested us-
ing TaqMan real-time PCR Kit (Applied Biosystems, 
Carlsbad, CA, USA) according to the instruction. The 
levels of U6 were used as an internal control.  
Transient transfection and luciferase assay
Reporter plasmids containing ERBB3 3’ UTR re-
gion with miR-148a binding site (wild type) or mu-
tation binding site (mutant) were cloned into pMIR-
REPORTER. HEK293 cells were seeded in 24-well 
plates and cultured overnight.  To investigate whether 
miR-148a directly regulates ERBB3 transcriptional 
expression by binding to the miR-148a binding site 
of ERBB3, pre-miR-148a or pre-miR-SCR was co-
transfected with plasmid pGL4.74 expressing renilla 
luciferase and the ERBB3 wild type or mutant reporter 
plasmid. After cultured for 48 h, cells were lysed with 
passive lysis buffer (Promega, WI, USA), renilla and 
firefly luciferase activities were measured using the 
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dual luciferase assay system (Promega WI, USA). 
ERBB3 transcriptional activity was normalized to re-
nilla luciferase activity, which was an internal control 
for transfection efficiency. Each experiment was re-
peated at least three times.
Immunoblotting assay
Cells were harvested and lysed on ice for 30 min 
in RIPA buffer (150 mmol/L NaCl, 100 mmol/L 
Tris, pH 8.0, 0.1% SDS, 1% Triton X-100, 1% so-
dium deoxycholate, 5 mmol/L EDTA and 10 mmol/
L NaF) supplemented with 1 mmol/L sodium vanad-
ate, 2 mmol/L leupeptin, 2 mmol/L aprotinin, 1 mmol/
L phenylmethylsulfonyl fluoride (PMSF), 1 mmol/
L DTT, and 2 mmol/L pepstatin A. The lysates were 
centrifugated, and the supernatants were collected as 
total cellular protein extracts. The total protein ex-
tracts were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE), and transferred to ni-
trocellulose membranes in transfer buffer (20 mmol/
L Tris-HCl, pH 8.0; 150 mmol/L glycine; 20% (v/v) 
methanol).  Membranes were blocked with 5% nonfat 
dry milk in 1×PBS containing 0.05% Tween 20, and 
incubated with specific antibodies. The protein bands 
were detected by incubation with horseradish perox-
idase-conjugated antibodies, and visualized with the 
SuperSignal West Pico Chemiluminescent Substrate 
Kits (Thermo Scientific, MA, USA).
Angiogenesis assay on chicken chorioallan-
toic membrane (CAM)
Fertilized chicken eggs were purchased from SPA-
FAS (Preston, CT, USA), and incubated at 37°C with 
70% humidity. On day 8, an artificial air sac was cre-
ated and a small window in the shell over the artificial 
air sac was cut as we described[37]. MCF7-miR-148a 
or MCF7-miR-SCR stable cells were resuspended in 
serum-free medium, and mixed with equal volume of 
Matrigel.  Then, aliquots (3×106, 40 μL) of the mix-
ture were applied onto the CAM of 9-d-old embryos. 
The area around the implanted Matrigel was photo-
graphed 5 d after the implantation, and the number of 
blood vessels was obtained by counting the branching 
of blood vessels. Assays for each treatment were car-
ried out using 8 chicken embryos.
Cell proliferation assay
To investigate the effects of miR-148a on the cell 
growth of MCF7 cells, the stable cell MCF7-miR-
SCR and MCF7-miR-148a were seeded in a 96-well 
plate (1,000 cells per well) and incubated at 37°C in 
5% CO2 incubator. The proliferation of the cells was 
measured using a proliferation assay kit, CCK8 kit 
(Dojindo Laboratories, Kumamoto, Japan) according 
to the manufacturer’s instruction. Results were ob-
tained from three independent experiments.
Statistical analysis
All values in the present study were reported as mean 
±SE. Student’s unpaired t test was used for statistical 
analyses. Differences between values were considered 
significant at P < 0.05.
RESULTS
MiR-148a expression in breast cancer cells 
To determine whether the expression of miR-148a 
is downregulated in breast cancer cells, human breast 
cancer cell lines MCF7 and T47D and the immor-
talized normal breast epithelial cells MCF10A were 
used to test the levels of miR-148a by TaqMan real-
time RT-PCR analysis. The results showed that miR-
148a expression was significantly decreased in MCF7 
and T47D cells (P < 0.05, Fig. 1A). To investigate the 
role of miR-148a in breast cancer, MCF7 cells were 
infected with lentiviruses expressing miR-148a and 
miR-SCR control, and selected by puromycin to obtain 
stable cell lines. We established stable cells with fluo-
rescent and contrast phase representative pictures of 
MCF7-miR-SCR and MCF7-miR-148a cells (Fig. 1B). 
Compared to MCF7-miR-SCR, the miR-148a level 
in MCF7-miR-148a was much higher (Fig.1C). These 
results indicated that we successfully established the 
stable breast cancer cell lines expressing miR-SCR and 
miR-148a, respectively.
ERBB3 acting as a direct target of miR-148a
To determine the direct target gene(s) of miR-148a, 
we identified the potential binding sites of miR-148a 
using the combination of PicTar, TargetScan and 
FindTar software, and found that ERBB3 was one of 
the predicted targets that contain putative conserved 
miR-148a binding sites within its 3’UTR. The binding 
site of miR-148a in ERBB3 3’-UTR region is highly 
conserved among several different species (Fig. 2A). 
To test whether miR-148a regulates ERBB3 expression 
at protein level, total proteins prepared from MCF7-
miR-148a cells and MCF7-miR-SCR cells were ana-
lyzed by Western blotting. Overexpression of miR-
148a greatly decreased ERBB3 expression in MCF7-
miR-148a cells (Fig. 2B), suggesting that ERBB3 is a 
downstream target of miR-148a. To further determine 
whether ERBB3 is a direct target of miR-148a, we 
constructed luciferase reporters containing ERBB3 3’-
UTR regions and the predicted binding site of miR-
148a (WT, Fig. 3A), or the predicted binding site with 
the mutation in the seed sequence (Mut, Fig. 3A). 
MCF7 cells were transfected with the ERBB3 reporter 
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plasmids in the absence or presence of lentivirus plas-
mids carrying miR-148a and miR-SCR. We found that 
miR-148a significantly inhibited ERBB3 wild type 
reporter activities, but not the mutant reporter activ-
ity (Fig. 3B). This result shows that miR-148a inhib-
its ERBB3 wild type reporter activities through the 
binding of miR-148a in the seed region. These results 
demonstrate that ERBB3 is a direct target of miR-148a 
in breast cancer cells.
Fig. 2 MiR-148a targeted to ERBB3. A: Putative binding 
site of ERBB3 3’-UTR by miR-148a. The seed-matching sites 
were predicted by PicTar, TargetScan and FindTar software, 
and were marked in red. DNA sequences of potential miR-148a 
binding site predicted within the human ERBB3 3’-UTR were 
also highly conserved among other species. B: MCF7 cells 
expressing scramble miRNA precursor (SCR) or miR-148a 
were used for Western blot analysis to determine the levels of 
ERBB3 expression with GAPDH as an internal control.
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MiR-148a inhibited the activation of AKT, ERK, 
and p70S6K1 and decreased HIF-1α expression. 
AKT and ERK signaling pathways are two key 
downstream pathways of ERBB3, and play important 
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Fig. 3 MiR-148a interacted with ERBB3 3’-UTR to 
inhibit its transcriptional activation. A: Schematic il-
lustration of ERBB3 3’-UTR wild type (WT) and mutant re-
porter constructs with the seed-matching sites marked in red. 
B: MCF7 cells were transfected with ERBB3 3’-UTR wild type 
(WT) and mutant reporter constructs in the presence of scram-
ble miRNA precursor (SCR) or miR-148a, and the cells were 
cultured for 36 h after the transfection. Relative luciferase ac-
tivities were measured and calculated as the ratio of firefly/re-
nilla activities in the cells, and normalized to those of the SCR 
control. The results were presented as means±SE from three 
independent experiments, *P < 0.05.
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Fig. 1 Endogenous and forced expression of miR-148a in breast cancer cells. A: Total RNAs from human breast cancer 
cells MCF7 and T47D and immortalized normal breast epithelial cells MCF10A were subjected to TaqMan real-time RT-PCR analy-
sis for miR-148a expression, *P < 0.05. B: MCF7 cells were infected by lentivirus carrying scrambled miRNA precursor (SCR) or 
miR-148a, and cultured in the medium containing puromycin to select and obtain stable cell lines. The red images on the left panels 
showed the expression of the lentivirus in the cells. C: MiR-148a expression levels in the cells were analyzed by stem-loop RT-PCR 
assay, and U6 expression levels were used as an internal control for RNA loading.
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roles in angiogenesis and cancer development[24,25]. To 
investigate the effect of miR-148a on their activation, 
we showed that levels of phospho-AKT (p-AKT) and 
phospho-ERK1/2 (p-ERK1/2) were greatly suppressed 
in the cells expressing miR-148a (Figs. 4A to 4D), in-
dicating that miR-148a inhibited ERBB3 expression 
with functional role by decreasing downstream AKT 
Overexpression of miR-148a inhibited tumor 
angiogenesis in vivo
In order to study whether overexpression of miR-
148a inhibits tumor angiogenesis, MCF7 cells ex-
pressing miR-148 and miR-SCR were resuspended in 
serum-free medium and used for angiogenesis assay 
on the chicken CAM of 9-d-old chicken embryos. The 
angiogenesis responses were analyzed on the CAM 
4 d after the implantation. MCF7 breast cancer cells 
induced the angiogenesis responses 4-fold higher than 
the normal angiogenesis in the CAM, and the forced 
expression of miR-148a significantly inhibited cancer 
cell-inducing angiogenesis responses by 45% (Fig. 
5B). Meanwhile, cell proliferation assay indicated that 
the growth rate of MCF7-miR-SCR was similar to that 
of MCF7-miR-148a, indicating that the angiogenesis 
response was not due to the effect of miR-148a over-
expression on cell proliferation (Fig. 5C). These results 
suggest that overexpression of miR-148a specifically 
inhibits angiogenesis.
DISCUSSION
MiRNAs act as tumor suppressors or oncogenes in 
a variety of cancers including breast cancer. Angio-
genesis is the process by which new blood capillaries 
are generated from the pre-existing vasculature. Ang-
iogenesis is important for tumor growth, development, 
and metastasis since tumors cannot grow larger than 
1-2 mm in diameter without an efficient blood sup-
ply[26]. Growing evidence demonstrates that miRNAs 
such as miR-378, miR-296, and the miR-17~92 cluster 
can regulate angiogenesis[27-29]. However, the role of 
miR-148a in tumor angiogenesis is unknown.  ERBB3 
is involved in regulating cancer initiation, tumor me-
tastasis and angiogenesis and is important in breast 
cancer development[30,31]. In addition, ERBB3 is in-
volved in acquired resistance to chemotherapy[32,33].  In 
A                                                            B                                                          C                                                           D
E                                                                  F                                                         G
SCR       miR-148a
ERBB3
β-actin
p-AKT
AKT
p-ERK1/2
ERK
miR-SCR   miR-148a
p-p70S6K1
p70S6K1
HIF-1α
β-actin
Fig. 4 MiR-148a inhibited AKT and ERK activation, and HIF-1α expression. Stable breast cancer cells expressing 
scramble miRNA precursor (SCR) or miR-148a were obtained by puromycin selection. A:The protein levels of ERBB3, β-actin, p-
AKT, total AKT, p-ERK1/2, and total ERK were analyzed by Western blotting. The relative densities of total ERBB3 (B), p-AKT (C), 
and p-ERK1/2 (D) levels were quantified and analyzed by Image J software from three replicate experiments, *P < 0.05. E: The pro-
tein levels of p-p70S6K1, total p70S6K1, HIF-1α, and β-actin were analyzed by Western blotting. The relative densities of p-p70S6K1 
(F) and HIF-1α (G) levels were quantified and analyzed by Image J software from three independent experiments, *P < 0.05.
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and ERK activation. Furthermore, miR-148a over-
expression inhibited p70S6K1 activation and HIF-
1α expression (Fig. 4E to 4G). Given the pivotal roles 
of these ERBB3 downstream molecules in regulating 
tumor growth and angiogenesis, these results indicate 
that miR-148 may inhibit tumor angiogenesis via tar-
geting ERBB3 and its downstream molecules.   
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this study, we demonstrated that the level of miR-148a 
in breast cancer cells MCF7 was lower than that in 
immortalized normal breast epithelial cells MCF10A, 
and ERBB3 is a direct target of miR-148a. This data 
show that miR-148a is a new regulator of ERBB3 in 
cancer cells, and the downregulation of miR-148a is a 
novel molecular mechanism for breast cancer devel-
opment. 
ERBB3 can heterodimerize with ERBB2 to activate 
AKT and ERK signaling pathways in different cells. 
Consistent with ERBB3 inhibition, forced expression 
of miR-148a in breast cancer cells inhibited the ac-
tivation of ERBB3 downstream molecules including 
AKT, ERK1/2, and p70S6K1. MiR-148a also sup-
pressed HIF-1α expression, which is a rate-limiting 
subunit for forming functional HIF-1 transcription 
factor. HIF-1 regulates the expression of VEGF and 
other angiogenesis regulators[34]. Thus, we hypoth-
esize that miR-148a inhibits breast tumor angiogen-
esis. To support this hypothesis, we demonstrated 
that miR-148a overexpression attenuated breast tumor 
angiogenesis induced by MCF7 cells. In summary, 
this study demonstrates that miR-148 directly targets 
ERBB3 through the seed sequence binding site at its 
3’-UTR. Reduced expression of miR-148a in breast 
cancer cells leads to the elevation of ERBB3 expres-
sion to activate AKT and ERK1/2 signaling pathways, 
which may in turn increase p70S6K1 activation and 
HIF-1α expression. miR-148a attenuates angiogenesis 
likely through directly inhibiting ERBB3 for transmit-
ting the signals to its downstream signaling molecules.
Our findings suggest that miR-148a/ERBB3 pathway 
would be a promising therapeutic target for breast 
cancer in the future.
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